Regenerative medicine company ViaCyte announced “the recent issuance of more than 200 patents, which provide protection to the company’s core technologies around the world.”
ViaCyte said the newly-issued patents further strengthen its position “in pluripotent cell-derived and implantable cell replacement therapies for insulin-requiring diabetes and other potential indications.”
“The newly issued composition of matter, method, and design patents include over 110 patents in Europe, 18 patents in the US, 14 patents in Japan, and 52 patents in other Asian/Pacific countries including China, Hong Kong, Singapore, South Korea, and Australia,” said ViaCyte.
“With the newly issued patents, ViaCyte’s patent portfolio now includes over 700 issued patents worldwide, and protection in the space extends for the next two decades or more.
“Many of the newly issued patents protect intellectual property that originated at Janssen Biotech, Inc., in its BetaLogics division, including patents directed to later stage pancreatic endocrine cells.
“ViaCyte’s acquisition of the BetaLogics assets in 2016 bolstered the Company’s intellectual property portfolio substantially by combining the patent estates and know-how of the two leaders in the field.”
ViaCyte CEO Paul Laikind said: “ViaCyte’s intellectual property covers directed differentiation to various cell types from numerous pluripotent stem cell sources, including embryonic and induced pluripotent stem cells, by multiple methods, as well as delivery and encapsulation devices for cell replacement therapies.
“Highlighted by the newly issued patents, we believe that ViaCyte has all of the elements it needs to successfully deliver transformative cell therapies for insulin-requiring diabetes, including cell and device platform technologies, know-how, expertise, intellectual property, and clinical and manufacturing experience.”